The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer's disease patients

American Journal of Pathology

Volumn 155, Issue 3, 1999, Pages 863-868

  Montine, Thomas J ^a,b   Markesbery, William R ^c   Zackert, William ^b   Sanchez, Stephanie C ^b   Roberts II, L Jackson ^a,b   Morrow, Jason D ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; ARACHIDONIC ACID; ISOPROSTANE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC MARKER; GENOTYPE; HUMAN; LIPID BRAIN LEVEL; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; NEUROFIBRILLARY TANGLE; PRIORITY JOURNAL;

EID: 0032886795     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65185-1     Document Type: Article

References (36)

1. Markesbery WR, Carney JM: Oxidative alterations in Alzheimer's disease. Brain Pathol 1999, 9:133-146
2. Smith M, Sayre L, Monnier V, Perry G: Radical AGEing in Alzheimer's disease. Trends Neurosci 1995, 18:172-176
3. Smith M, Sayre L, Perry G: Is Alzheimer's a disease of oxidative stress? Alzheimer's Dis Rev 1996, 1:63-67
4. Lovell M, Ehmann W, Butler S, Markesbery W: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995, 45:1594-1601
5. Markesbery WR, Lovell MA: 4-Hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998, 19:33-36
6. Montine K, Olson S, Amarnath V, Whetsell W, Graham D, Montine T: Immunochemical detection of 4-hydroxynonenal adducts in Alzheimer's disease is associated with APOE4. Am J Pathol 1997, 150:437-443
7. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ: 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 1997, 56:866-871
8. Montine K, Reich E, Olson SJ, Markesbery WR, Montine T: Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype. J Neuropathol Exp Neurol 1998, 57:415-425
9. Pappolla MA, Omar RA, Kim KS, Robakis NK: Immunohistochemical evidence of antioxidant stress in Alzheimer's disease. Am J Pathol 1992, 140:621-628
10. Sayre LM, Zelasko DA, Harris PLR, Perry G, Salomon RG, Smith MA: 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer disease. J Neurochem 1997, 2092-2097
11. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR: Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc Natl Acad Sci USA 1991, 88:10540-10543
12. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G: Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994, 145:42-47
13. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N: Oxidative damage in Alzheimer's. Nature 1996, 382:120-121
14. Smith MA, Sayre LM, Monnier VM, Perry G: Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol 1996, 28:41-48
15. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, Perry G: Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J Histochem Cytochem 1998, 46:731-735
16. Gutteridge JMC, Halliwell B: The measurement and mechanism of lipid peroxidation in biological systems. Trends Biochem Sci 1990, 15:129-135
17. Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991, 11:81-128
18. Morrow J, Hill K, Burk R, Nammour T, Badr K, Roberts L: A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proc Natl Sci USA 1990, 87:9383-9387
19. Morrow JD, Roberts LJ: The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997, 36:1-21
20. Pratico D, Barry OP, Lawson JA, Adiyaman M, Hwang SW, Khanapure SP, Iuliano L, Rokach J, Fitzgerald GA: IPF2-α-I - an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998, 95:3449-3454
21. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ: Cerebrospinal fluid F2-isoprostanes are increased in Alzheimer's disease. Ann Neurol 1998, 44:410-413
22. 2-isoprostane concentration in probable Alzheimer's disease. Neurology 1999, 52:562-565
23. Pratico D, Lee VM, Trojanowski JQ, Rokach J, Fitzgerald GA: Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998, 12:1777-1784
24. Coyle JT, Puttfarcken P: Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993, 262:689-695
25. Beal MF: Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 1995, 38:357-366
26. Bowling AC, Beal MF: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1994, 56:1151-1171
27. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
28. Braak H, Braak E: Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259
29. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenova M, Gabbita SP, Wu JF, Lovell M, Markesbery WR, Butterfield DA: Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 1995, 65: 2146-2156
30. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L, Goldgaber D, Manwaring MG, Szymanski MH, McCown N, Roses A: Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993, 342:710-711
31. Morrow JD, Roberts LJ: Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical catalyzed mechanism. Methods Enzymol 1994, 233:163-174
32. Kjeldsberg CR, Krieg AF: Cerebrospinal fluid and other body fluids. Clinical Diagnosis and Management by Laboratory Methods, ed 17. Edited by JB Henry. Philadelphia, W B Saunders Co, 1984, pp 459-492
33. Dickson DW: Aging in the central nervous system. Neuropathology of Dementing Disorders. Edited by WR Markesbery. New York, Arnold, 1998, pp 56-88
34. Davis DG, Schmitt FA, Wekstein DR, and Markesbery WR: Alzhiemer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999, 58:376-388
35. Mahley R, Nathan B, Bellosta S, Pitas R: Apolipoprotein E: impact of cytoskeletal stability in neurons and the relationship to Alzheimer's disease. Curr Opin Lipidol 1995, 6:86-91
36. Pitas RE, Ji ZS, Weisgraber KH, Mahley RW: Role of apolipoprotein E in modulating neurite outgrowth: potential effect of intracelular apolipoprotein E. Biochem Soc Trans 1998, 26:257-262